For Cardiologists looking for a self-applied, out-of-the-box solutions for clinical practice. Our latest product, available on prescription, is a medical device that records and transfers single-channel ECG and provides automated detection of atrial fibrillation and other arrythmias.
Are you a patient thats interested? Register Here to learn how your healthcare team can give you a prescription.
Monitor multiple users simultaneously with an easy-to-use dashboard. Live streaming of the ECG allows you to validate the quality of the signal remotely.
Use our tools for hospitals & researchers to manage multiple patient accounts. Receive notifications on activity and download raw ECG data.
Summary trend lines of select metrics can support early decision making and refine decisions for your patients, employee groups, and trial participants.
Roberts, William O. MD, MS, FACSM1; Levine, Benjamin D. MD, FACSM2
A case report of a 16-year-old competitive runner experienced sudden-onset tachycardia episodes, exceeding 200 bpm, were documented using a Garmin Instinct™ watch. Despite normal cardiac evaluations, The patient later used a Frontier X™ ECG Fitness Tracker, which successfully captured heart rhythm data during episodes and helped monitor his response to beta blocker therapy.
Ciara McCormack, Brona Kehoe, Sarah Cullivan, Noel McCaffrey, Sean Gaine, Brian McCullagh, Andrew McCarren, Sarah J Hardcastle, Niall M Moyna
The Frontier X device played a crucial role in continuously monitoring heart rate and respiratory rate, ensuring safety and enabling real-time feedback during the exercise sessions. The success of this remotely delivered intervention suggests that similar models could be effectively implemented for broader PH patient populations, offering a scalable alternative to hospital-based programs.
This study aimed to validate the Frontier X+ (FX+) single-lead, continuous ECG device by comparing its performance against the traditional FDA Cleared 12-lead ECG in 832 patients in both a clinical and real world setting including individuals with and without atrial fibrillation (AFib). The performance of the Frontier X+ in detecting atrial fibrillation (AF) demonstrated a sensitivity of 98.10% and a specificity of 97.88%, when compared to the paired gold standard device as adjudicated by 3 independent cardiologists.
Unified cloud for ECG, participant data, research notes, and activity.
Downloadable Raw Data
Customised support & service.
Note:
The Frontier X Plus (FX+) is a prescription only US FDA 510(k) cleared medical device for ambulatory ECG monitoring. It is not tested for use in individuals with pacemakers or ICDs. It is not meant for the diagnosis of cardiac ischemia. Please request the IFU for intended use, indications, contraindications and availability in your geography.